Literature DB >> 11912857

The New England division Tell A Friend program implementation evaluation.

N Passanisi1, M Prout, L J Holm.   

Abstract

Tell A Friend (TAF) is the nationwide program of the American Cancer Society that aims to decrease breast cancer mortality by encouraging unscreened women to have mammograms using a peer-to-peer approach. An evaluation via the Collaborative Evaluation Fellows Project attempted to identify barriers and facilitators to successful implementation of TAF in the New England division. The proposed method included three surveys; this was revised because of a low response rate to the initial e-mailed survey. The actual method included one shortened survey and one follow-up survey. Results are presented for an initial and shortened survey for staff and a follow-up survey of respondents. Initial TAF implementation timelines were unrealistic, and the field staff encountered many barriers to implementation of TAF in the targeted communities. Changes are being made in training, management, and resources to ensure successful implementation. Continuous re-evaluation is planned to ensure the successful implementation and conduct of the program.

Entities:  

Mesh:

Year:  2001        PMID: 11912857     DOI: 10.1046/j.1523-5394.2001.95111.x

Source DB:  PubMed          Journal:  Cancer Pract        ISSN: 1065-4704


  3 in total

1.  Consistency in attitudes across cancer screenings in medically underserved minority populations.

Authors:  Susan J Shaw; James Vivian; Kathryn M Orzech; Cristina Huebner Torres; Julie Armin
Journal:  J Cancer Educ       Date:  2012-03       Impact factor: 2.037

2.  Intermittent attendance at breast cancer screening.

Authors:  Padraic Fleming; Sinead O'Neill; Miriam Owens; Therese Mooney; Patricia Fitzpatrick
Journal:  J Public Health Res       Date:  2013-09-05

3.  Lifetime utilization of mammography among Maltese women: a cross-sectional survey.

Authors:  Danika Marmarà; Vincent Marmarà; Gill Hubbard
Journal:  BMC Public Health       Date:  2018-01-25       Impact factor: 3.295

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.